Inflammation in pulmonary artery hypertension

Vascul Pharmacol. 2019 Jul-Aug:118-119:106562. doi: 10.1016/j.vph.2019.05.002. Epub 2019 May 18.

Authors

Masashi Sakuma¹, Shigeru Toyoda², Teruo Inoue², Koichi Node³

Affiliations

¹ Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Tochigi 321-0293, Japan. Electronic address: masakuma@dokkyomed.ac.jp.
² Department of Cardiovascular Medicine, Dokkyo Medical University, Mibu, Tochigi 321-0293, Japan.
³ Department of Cardiovascular Medicine, Saga University, Saga 849-8501, Japan.

PMID: 31112745
DOI: 10.1016/j.vph.2019.05.002

No abstract available

Publication types

Review

MeSH terms

Animals
Anti-Inflammatory Agents / therapeutic use
Antihypertensive Agents / therapeutic use
Arterial Pressure* / drug effects
Bone Morphogenetic Protein Receptors, Type II / metabolism
HMGB1 Protein / metabolism
Humans
Hypertension, Pulmonary / drug therapy
Hypertension, Pulmonary / metabolism*
Hypertension, Pulmonary / physiopathology
Inflammation / drug therapy
Inflammation / metabolism*
Inflammation / physiopathology
Inflammation Mediators / metabolism*
Pulmonary Artery / drug effects
Pulmonary Artery / metabolism*
Pulmonary Artery / physiopathology
Signal Transduction
Toll-Like Receptor 4 / metabolism
Vascular Remodeling* / drug effects

Substances

Anti-Inflammatory Agents
Antihypertensive Agents
HMGB1 Protein
Inflammation Mediators
Toll-Like Receptor 4
Bone Morphogenetic Protein Receptors, Type II